Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994357 | 1.00 | HPGDS (0.65) | HPGDSGABRA5MAP4K4PRKAB2PRKAG1 | |
| SCHEMBL3092680 | 0.91 | HPGDS (0.60) | HPGDSGABRA5MAP4K4PRKAB2PRKAG1 | |
| SCHEMBL2989735 | 0.91 | HPGDS (0.60) | HPGDSGABRA5MAP4K4PRKAB2PRKAG1 | |
| SCHEMBL2989738 | 0.91 | HPGDS (0.60) | HPGDSGABRA5MAP4K4PRKAB2PRKAG1 | |
| SCHEMBL2984485 | 0.90 | HPGDS (0.63) | HPGDSGABRA5MAP4K4ACACBACACA | |
| SCHEMBL2984489 | 0.90 | HPGDS (0.63) | HPGDSGABRA5MAP4K4ACACBACACA | |
| SCHEMBL2994529 | 0.89 | HPGDS (0.66) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL2985631 | 0.89 | HPGDS (0.66) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL2985636 | 0.89 | HPGDS (0.66) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL2996580 | 0.88 | HPGDS (0.65) | HPGDSGABRA5MAP4K4ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885GABRA5 1938/4885MAP4K4 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.